We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

Canada's approach to functional foods
  • Torys LLP
  • Canada
  • April 21 2010

Today’s diet- and health-conscious environment has led to a proliferation of functional food marketing claims that advertise the specific health-enhancing characteristics of a food product


Ontario companies doing business with hospitals may become subject to access-to-information requests
  • Torys LLP
  • Canada
  • April 6 2011

Pharmaceutical and medical device companies doing business with Ontario organizations that accept public funding, including hospitals, may be affected by recent legislative amendments aimed at increasing transparency and accountability of these entities


Health Canada to list authorized clinical trials online
  • Torys LLP
  • Canada
  • October 25 2012

On October 18, 2012, Health Canada issued a news release and subsequent Drugs and Health Products Notice announcing that it will create a web-based list of clinical trials authorized by Health Canada


Ontario court confirms generic drug manufacturers not entitled to unjust enrichment
  • Torys LLP
  • Canada
  • January 22 2013

On January 15, 2013, the Ontario Superior Court of Justice (Ontario Court) granted a motion for partial summary judgment in Apotex Inc. v. Abbott


Canada’s PAAB releases updated Code of Advertising Acceptance
  • Torys LLP
  • Canada
  • December 7 2012

The Pharmaceutical Advertising Advisory Board (PAAB) has released a revised version of its Code of Advertising Acceptance


Biosimilars in Canada: new draft guidelines from Health Canada
  • Torys LLP
  • Canada
  • July 21 2009

Health Canada announced that it had granted marketing authorization for Omnitrope (a human growth hormone), the first subsequent entry biologic (SEB) to be approved for sale in Canada


Canada’s Federal Court of Appeal limits damages available to delayed generics
  • Torys LLP
  • Canada
  • June 8 2009

On June 4, 2009, in Merck Frosst Canada Inc. v. Apotex, Inc., the Federal Court of Appeal released an important decision limiting the range of damages available in actions under section 8 of the Patented Medicines (Notice of Compliance) Regulations


More biopharma M&A in 2010, but healthy or distressed?
  • Torys LLP
  • Canada
  • December 31 2009

As blockbuster drugs began to come off patent, big pharmas fearing loss of revenue share rushed to couple with their counterparts in 2009


Data protection in Canada: Court of Appeal confirms narrow approach
  • Torys LLP
  • Canada
  • January 30 2013

On January 18, 2013, the Federal Court of Appeal (FCA) released its decision in Takeda Canada Inc. v. The Minister of Health and Attorney General of


Canada’s regulation of subsequent entry biologics
  • Torys LLP
  • Canada
  • April 6 2009

Health Canada has released a revised version of the draft guidance document "Information and Submission Requirements for Subsequent Entry Biologics."